Theorem Clinical Research appoints vp of global regulatory affairs

Brian Bollwage is a food and drug law expert

Theorem Clinical Research appoints vp of global regulatory affairs

Theorem Clinical Research, a US contract research organisation (CRO), has appointed Brian Bollwage to the position of vice president of global regulatory affairs.

Bollwage was previously director of global regulatory science at Bristol-Myers Squibb and executive director and regulatory counsel of global regulatory intelligence at i3 Research.

He is a food and drug law expert and a graduate of Rutgers Law School. He currently serves as an associate professor of food and drug law at Temple University in Philadelphia.

You may also like

Research & Development

Chiltern to purchase Theorem Clinical Research

To expand its global reach and scientific expertise
Research & Development
Theorem opens clinical supplies facility in Frankfurt, Germany

Theorem opens clinical supplies facility in Frankfurt, Germany

The expansion will offer both ambient and refrigerated storage space
Ingredients
UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny

UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny

The agency's new biomonitoring study will investigate PFAS exposure across the UK, providing evidence as pharmaceutical manufacturers face growing pressure around the use of forever chemicals
You need to be a subscriber to read this article.
Click here to find out more.
Packaging
Embracing healthcare innovation with 2D codes

Embracing healthcare innovation with 2D codes

Pharmaceutical manufacturers already serialise medicines using 2D codes to meet regulatory requirements, but a 2D code can be so much more than a tick box for compliance, explains Ian Chapman, Strategic Manager for Digital Coding at Domino Printing Sciences
Manufacturing
Pace Life Sciences completes EMA GMP inspection at New Jersey CDMO facility

Pace Life Sciences completes EMA GMP inspection at New Jersey CDMO facility

The inspection supports renewal of the EU GMP certificate at the company's New Jersey site, which provides pharmaceutical analytical testing, microbiology and development services
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing
UK Budget 2026: what it means for pharma manufacturing

UK Budget 2026: what it means for pharma manufacturing

VAT relief on free medicines, £1bn in new investment and revised capital allowances give pharma manufacturers progress — but gaps remain
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory
A completed reply is not a finalised case: how to test AI intake in pharma

A completed reply is not a finalised case: how to test AI intake in pharma

A medical information response marked complete says nothing about safety information that arrives later. Before accepting an AI intake demonstration, ask to see what happens to the next message: who assesses it, what stays pending and which dates are preserved
Subscribe now